Correlation between soluble urokinase plasminogen activator receptor with CD4 T lymphocyte and WHO clinical staging of HIV infection

Shinta Oktya Wardhani, Niniek Burhan, Gatoet Ismanoe, Tri Yudani

Abstract views = 462 times | downloads = 297 times


The urokinase-type plasminogen activator (uPA) and its receptor play a key role in pericellular proteolysis, cell migration and signal transduction. Previous study showed that suPAR could be used as an independent prognostic marker of disease progression in HIV-1 patients.1,17 Immune status of HIV patient and progressivity of disease are important parameters used as clinical concideration before initiating anti retroviral treatment and for monitoring treatment effectivity. Recently immune status of HIV patients is determined by CD4 T lymphocyte counting which represents the remaining healthy lymphocyte T expressing CD4 that very expensive and need special laboratory equipment. Destruction and shedding of T lymphocyte, macrophage and natural killer cell will deliver soluble urokinase plasminogen activator receptor, a surface protein which is expressed by those cells and can be measured by ELISA8,9,11. This study objective is to determine correlation between suPAR plasma concentration and CD4 T lymphocyte and WHO clinical stagging of HIV infection. Study subjects. Fifty four naieve HIV-1-infected patients (32 males, and 22 females) are participant in a cross sectional study enrolled on 22 November 2007 until 31 july 2008 at the department of infectious disease Saiful Anwar Hospital, Malang, Indonesia. Blood sampling. Two blood samples were drawn before treatment, CD4 counts were measured with an Epics XL-MCL Coulter flowcytometer. EDTA plasma for suPAR measurement was stored at -80°C. Data are presented as mean±standart deviation. P<0.05 is considered significant. Statistical calculations were done using SSPS 15. Patients (n = 54) enrolled and clustered according to WHO clinical stage ( I - IV) at inclusion. All HIV-infected patients had measurable levels of plasma suPAR with a median value of 8,9 ng/mL(range 1,65-29,7 ng/mL). Pearson correlation demonstrated a weak but significant negative between suPAR and CD4 T lymphocyte count (p=-0.634, p<.0005). suPAR level positively correlated with the WHO-defined clinical stages (P< .0005, spearman correlation test, r=0,87). There were significant difference between each stage i.e I(1,6± o,61ng/mL), II(3.04±1.03 ng/mL), III (10.53±7.1ng/mL) and IV (20.42±10.81ng/mL) (P< .0005, Spearman test). In addition pearson correlation demonstrated a weak but significant negative correlation between suPAR and CD4 count (p=-0.66; P<.0005). There were negative significant correlatio between CD4 count and suPAR level, suggested that suPAR could provide as a complementary biological marker for HIV-1 although it can not replace the CD4 count. SuPAR plasma concentration and clinical stage give significantly correlation with WHO clinical staging of HIV infection.


suPAR, HIV, CD4 T lymphocyte, WHO clinical stage

Full Text:



WHO/UNAIDS, Summary country profile for HIV/AIDS treatment scale up: Indonesia June 2005.

Hammer Scott, Management of newly diagnosed HIV infection, N Enl J Med, 353; 16; 2005.

Musey Luwy, James Hughes, Timothy Schacker, Theresa Shea, Lawrence Corey, and Juliana Mc Elrat, Cytotoxic-T-Cell Responses, Vial load and disease progession in early Human Immunodeficiency virus type 1 infection, N Engl J Med; 337: 18, 1997.

Langford Simone E, Jintanat Ananworanich and David A Cooper, Predictor of diesease progression in HIV infection: a review, AIDS Research and Therapy 2007, 4: 11.

Fauci AS, Pantaleo G, Stanley S. Immunopathogenic mechanisms of HIV infection, Ann Intern Med, 1996; 124: 654–653.

Calles N.R, Evans D, Terlonge DeLouis, Pathophysiology of the

human immunodeficiency virus, Weill Medical College of Cornell

University. Available at:

PathNotes/HIV_Infection/HIV_Infection_04. Di akses September

Paranjape RS. Immunopathogenesis of HIV infection. Indian J Med Res 2005; 121: 240–55.

Kilbi J.Michael, Eron Joshep, Novel therapies based on mechanism of HIV-1 Cell Entry, N Engl J Med 348; 22, 2003

Nasronudin. The Effect of HIV/AIDS Infection Diagnosis to TCD4 Lymphocytes Apoptosis Mechanism in HIV/AIDS Patients,

Psychoneuroimmunoligical Approach. Thesis. Airlangga Univ.

Surabaya: 2005.

Blasi F, Carmeliet P. uPAR: A versatile signalling orchestrator. Nat. Rev.Mol.Cell Biol. 2002; 3: 750–54.

Montuori Nunzia, Maria vincenza Carriero, alvatore Salzano, Guido Rossi, and Pia Ragno, The Cleavage of tha Urokinase Receptor regulates its multiple functions,, 2002.

Murali Rama, Joshua H.Wolfe, Rebecca Erber, Seto M. Chice,

M.R.Murali, Helen G Durkin, Petr Zach and Dominick L.Auci,

Altered levels of urokinase on monocytes and in serm of children

with AIDS; effects on lymphocyte activation and surface marker

expression, J.Leukbio; 64, 1998.

Ostrowski. S.R, T. L.Katzenstein, G.Hoyer-Hansen, J.Gerstoft, B.K.Pedersen, H.Ullum, Plasma level of intact and cleaved urokinase receptor decrease in HIV-1-invected patients initiating Highly Active Antiretroviral Therapy, Scandinav J Immunol 2006; 63, 478–486.

Sidenius N, Sier CF, Ullum H. Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection, Blood 2000; 96: 4091–95.

Lawn SD, Myer L, Bangani N, Vogt M, Wood R, Plasma levels

of soluble urokinase-type plasminogen activator receptor (suPAR) and early mortality risk among patients enrolling for antiretroviral treatment in South Africa, BMC Infect Dis 2007; 7: 41.

Schneider Uffe, Nielsen RL, Pedersen Court, Olsen JE, The prognosis value of the suPARnostic TM ELISA assay in HIV-1 infected individuals is not affected by uPAR promoter polymorphisms, BMC infectious Disease 2007, 7: 134.

BD tritest CD3/CD4/CD4 reagent for flowcytometer equipped (BD Catalog no.340385)

Missionpharma, SuPARnostic ELISA Kit,, 2007.

Santoso,S. Buku Statistik Non Parametrik. Jakarta:Penerbit PT Elex Media Komputindo, 2003.

Dajan, A, Pengantar Metode Statistik, Jilid I, Pustaka LP3ES

Indonesia, Jakarta, 1995.

Kofoed Kristian, Ove Andersen, Gitte Kronborg, Mchae Tvede, Janne Petersen, Jasper Eugen-Olsen and Klaus Larsen, Use of plasma Creactive protein, procalcitonin, neutrophils, macrophage migration inhibitory factor, soluble urokinase-type plasminogen activator receptor, and soluble triggerring receptor expressed on myeloid cells-1 in combination to diagnose infections: a prospective study, Critical Care 2007, 11: R38.

Mangione CM, Gerberding JL, Cummings SR. Occupational exposure to HIV: frequency and rates of underreporting of percutaneous and mucocutaneous exposures by medical housestaff. Am J Med. 1991; 90: 85–90.

Nasronudin. Pencegahan penularan infeksi HIV dan AIDS melalui universal precaution. HIV & AIDS: Pendekatan Biologi Molekuler, Klinis dan Sosial. Airlangga University Press, Surabaya; 2007.

Nasronudin. HIV & AIDS: Intervensi HIV dan peran mitochondria. Pendekatan Biologi Molekuler, Klinis dan Sosial. Airlangga University Press, Surabaya; 2007.

Andersen Ove, Eugen-Olsen, Kofoed kristian, Iversen Johan,

Haugaard Steen B; Soluble Urokinase Plasminogen Activator

Receptor is a Marker of Dysmetabolism in HIV-Infected Patients

Receiving Highly Active Antiretroviral Therapy. Journal of medical

virology, 2008.

Friis Hendrik, Gomo Exnevia, et al. HIV and other predictors of serum folate, serum ferritin and hemoglobin in pregnancy: a cross-sectional study in Zimbabwe, Am J Clin Nutr; 73: 2001.

Djoba Siawaya JF, Ruhwald M, Eugen-Olsen J, Walzl G, Correlates for disease progression and prognosis during concurrent HIV/TB infection; Int J Infect Dis. Jul; 11(4): 289–99. 2007.

Ditjen PP dan PL 2005, Laporan triwulan pengidap infeksi HIV dan kasus AIDS sampai desember 2005, Jakarta Ditjend PP dan PI, Depkes RI, 2005.

KPA 2003, Strategi nasional penanggulangan infeksi HIV/AIDS 2003–2007. Kementrian Koordinator bidang kesejahteraan rakyat, Komisi nasional penanggulangan AIDS, 2003.

Ostrowski SR, Katzenstein TL, Piironen T, Gerstoft J, Pedersen BK, Ullum H. Soluble Urokinase Receptor Levels in Plasma During 5 Years of Highly Active Antiretroviral Therapy in HIV-1 Infected Patients. J Acquir Immune Defic Syndr 2004; 35: 337–42.

Ostrowski SR. The Soluble Urokinase Receptor in Inflammation-with Focus on HIV-Infection and Malaria. Ph.D.diss. Copenhagen Univ. Denmark; 2004.

Ostrowski. S.R, T. Piironen, G.Hoyer-Hansen, J.Gerstoft,

B.K.Pedersen, H.Ullum, Reduced release of intake and cleved

urokinase receptor in stimulated whole-blood cultures from Human Immunodeficiency Virus-1-infected patients, Scandinav J Immunol 2005; 61, 347–356.

Eugen-Olsen J, Gustafson P, Sidenius N, Fischer TK, Parner J, Aaby P, Gomes VF, Lisse I, The serum level of soluble urokinase receptor is elevated in tuberculosis patients and predicts mortality during treatment: a community study from Guinea-Bissau, Int J Tuberc Lung Dis. Aug; 6(8): 686–92, 2002.

Kronborg, N. Weis, H. Nielsen, N. Obel, S. S. Pedersen and J. Eugen-Olsen, The plasma level of soluble urokinase receptor is elevated in patients with Streptococcus pneumoniae bacteraemia and predicts mortality, Clin Microbiol Infect 2004; 10: 409–415.

Ostergaard C, Benfield T, Lundgren JD, Eugen-Olsen J Soluble urokinase receptor is elevated in cerebrospinal fluid from patients with purulent meningitis and is associated with fatal outcome; Scand J Infect Dis. 36(1):14–9 2004.


  • There are currently no refbacks.

Copyright (c) 2017 Indonesian Journal of Tropical and Infectious Disease

View My Stats

IJTID Indexed by : 


IJTID (pISSN 2085-1103eISSN 2356-0991is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Lembaga Penyakit Tropis (Institute of Tropical Disease)

Universitas Airlangga

Kampus C Mulyorejo

Surabaya 60115